{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:53:04Z","timestamp":1783075984684,"version":"3.54.6"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The purposes of this study were to assess drug interactions between rufinamide and concomitant antiepileptic drugs (AEDs) and to identify the therapeutic window for rufinamide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Serum samples (n = 1531) were obtained from 178 patients (aged 2\u201357 years), and clinical records were retrospectively reviewed to evaluate the safety and efficacy of rufinamide (mean observation time, 1073 \u00b1 846 days).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Rufinamide exhibited linear pharmacokinetics at doses of up to 60 mg\/kg (range, 50\u20133200 mg\/d). Concomitant use of the enzyme-inducing AEDs such as phenytoin, carbamazepine, and phenobarbital reduced rufinamide concentrations by 43.4%, 13.2%, and 30.3%, respectively. By contrast, concomitant use of valproate significantly elevated rufinamide concentrations. Clinical response was seen in 41 patients (23.0%), with a median therapeutic concentration (interquartile range) of 20.6 mcg\/mL (13.3\u201327.0). There was no difference in the therapeutic concentrations between seizure types, but patients with tonic\/atonic seizures tended to have higher rufinamide concentrations. During the study period, adverse events were reported in 64 patients (35.8%), including somnolence, gastrointestinal disorders, dizziness, and irritability\/behavior disorders. Conditional logistic regression analysis showed that patients administered a concentration greater than 20 mcg\/mL had an 8.6-fold higher incidence of adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring for rufinamide is clinically useful for predicting drug interactions between rufinamide and concomitant AEDs. When a patient has tonic\/atonic seizures, careful titration is required for concentrations greater than 20 mcg\/mL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000977","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T21:11:37Z","timestamp":1645823497000},"page":"585-591","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Drug Monitoring for Rufinamide in Japanese Patients With Epilepsy: Focus on Drug Interactions, Tolerability, and Clinical Effectiveness"],"prefix":"10.1097","volume":"44","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka, Japan; and"},{"name":"Laboratory of Clinical Pharmacokinetics and Drug Safety, Shizuoka General Hospital, Kita Ando, Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama, Shizuoka, Japan;"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"106211","DOI":"10.1016\/j.eplepsyres.2019.106211","article-title":"Rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy: a retrospective single center study","volume":"168","author":"Oesch","year":"2020","journal-title":"Epilepsy Res."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","article-title":"Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the American epilepsy society","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0b013e31820fa9ad","article-title":"Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication","volume":"33","author":"May","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejpn.2015.12.015","article-title":"Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study","volume":"20","author":"Arzimanoglou","year":"2016","journal-title":"Eur J Paediatr Neurol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-0032-1324403","article-title":"Rufinamide in children with refractory epilepsy: pharmacokinetics, efficacy, and safety","volume":"43","author":"Dahlin","year":"2012","journal-title":"Neuropediatrics"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.01.002","article-title":"Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial","volume":"121","author":"Ohtsuka","year":"2016","journal-title":"Epilepsy Res."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jat\/bku070","article-title":"Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases","volume":"38","author":"Deeb","year":"2014","journal-title":"J Anal Toxicol."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/187231211798472511","article-title":"Investigation of the metabolism of rufinamide and its interaction with valproate","volume":"5","author":"Williams","year":"2011","journal-title":"Drug Metab Lett."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/NDT.S185774","article-title":"Adjunctive rufinamide in children with lennox-gastaut syndrome: a literature review","volume":"16","author":"Balagura","year":"2020","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000350392","article-title":"A pharmacokinetic study and correlation with clinical response of rufinamide in infants with epileptic encephalopathies","volume":"91","author":"la Marca","year":"2013","journal-title":"Pharmacology"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","article-title":"Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan","volume":"108","author":"Ohtsuka","year":"2014","journal-title":"Epilepsy Res."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T21:00:32Z","timestamp":1748984432000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000977","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"2021-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}